Switch theme
Sign up to access all valuation multiples
Genomed SA assembles outstanding molecular biologists and genetic diagnosticians. The company provides diagnostic service that comprises DNA analysis and congenital diseases diagnostics based on DNA sequencing. It offers Diagnostic service and Service for scientific purposes.
2008
35
Last FY Revenue $6.1M
Last FY EBITDA $0.5M
$7.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Genomed achieved revenue of $6.1M and an EBITDA of $0.5M.
Genomed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genomed valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $6.1M | XXX | XXX | XXX |
| Gross Profit | XXX | $3.8M | XXX | XXX | XXX |
| Gross Margin | XXX | 63% | XXX | XXX | XXX |
| EBITDA | XXX | $0.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 8% | XXX | XXX | XXX |
| EBIT | XXX | $0.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | 5% | XXX | XXX | XXX |
| Net Profit | XXX | $0.3M | XXX | XXX | XXX |
| Net Margin | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Genomed's stock price is PLN 25 (or $7).
Genomed has current market cap of PLN 32.5M (or $8.6M), and EV of PLN 27.7M (or $7.3M).
See Genomed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.3M | $8.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Genomed has market cap of $8.6M and EV of $7.3M.
Genomed's trades at 1.2x EV/Revenue multiple, and 14.2x EV/EBITDA.
Equity research analysts estimate Genomed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Genomed's P/E ratio is not available.
See valuation multiples for Genomed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8.6M | XXX | $8.6M | XXX | XXX | XXX |
| EV (current) | $7.3M | XXX | $7.3M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 1.2x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 14.2x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 23.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 29.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1027.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGenomed's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Genomed's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Genomed's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Genomed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 8% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 58% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genomed acquired XXX companies to date.
Last acquisition by Genomed was XXXXXXXX, XXXXX XXXXX XXXXXX . Genomed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Genomed founded? | Genomed was founded in 2008. |
| Where is Genomed headquartered? | Genomed is headquartered in Poland. |
| How many employees does Genomed have? | As of today, Genomed has 35 employees. |
| Is Genomed publicy listed? | Yes, Genomed is a public company listed on WAR. |
| What is the stock symbol of Genomed? | Genomed trades under GEN ticker. |
| When did Genomed go public? | Genomed went public in 2011. |
| Who are competitors of Genomed? | Similar companies to Genomed include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Genomed? | Genomed's current market cap is $8.6M |
| Is Genomed profitable? | Yes, Genomed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
